X4 Pharmaceuticals, Inc (XFOR) stock
XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.98−0.11 (-3.56%)
Close on Nov 18, 2026Market cap $295.46MP/E –Yield –
X4 Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
X4 Pharmaceuticals's operating income for the twelve months ending Sep 30, 2026 was -$80.39M. For fiscal 2025 it was -$86.88M. The highest annual figure on record is -$22.25M in fiscal 2017.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$86.88M | – |
| FY2024 | Dec 31, 2024 | -$36.40M | – |
| FY2023 | Dec 31, 2023 | -$107.52M | – |
| FY2022 | Dec 31, 2022 | -$87.57M | – |
| FY2021 | Dec 31, 2021 | -$85.11M | – |
| FY2020 | Dec 31, 2020 | -$59.87M | – |
| FY2019 | Dec 31, 2019 | -$51.70M | – |
| FY2018 | Dec 31, 2018 | -$29.09M | – |
| FY2017 | Dec 31, 2017 | -$22.25M | – |
| FY2016 | Dec 31, 2016 | -$24.35M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$19.99M | – |
| Q2 FY2026 | Jun 30, 2026 | -$16.39M | – |
| Q1 FY2026 | Mar 31, 2026 | -$20.31M | – |
| Q4 FY2025 | Dec 31, 2025 | -$23.70M | – |
| Q3 FY2025 | Sep 30, 2025 | -$27.51M | – |
| Q2 FY2025 | Jun 30, 2025 | -$26.23M | -136.9% |
| Q1 FY2025 | Mar 31, 2025 | -$9.44M | – |
| Q4 FY2024 | Dec 31, 2024 | -$35.72M | – |
| Q3 FY2024 | Sep 30, 2024 | -$34.50M | – |
| Q2 FY2024 | Jun 30, 2024 | $71.10M | – |
| Q1 FY2024 | Mar 31, 2024 | -$37.29M | – |
| Q2 FY2023 | Jun 30, 2023 | -$25.81M | – |
| Q1 FY2023 | Mar 31, 2023 | -$29.30M | – |
| Q4 FY2022 | Dec 31, 2022 | -$25.58M | – |
| Q3 FY2022 | Sep 30, 2022 | -$20.15M | – |
| Q2 FY2022 | Jun 30, 2022 | -$20.57M | – |
| Q1 FY2022 | Mar 31, 2022 | -$21.27M | – |
| Q4 FY2021 | Dec 31, 2021 | -$29.06M | – |
| Q3 FY2021 | Sep 30, 2021 | -$19.12M | – |
| Q2 FY2021 | Jun 30, 2021 | -$19.00M | – |
| Q1 FY2021 | Mar 31, 2021 | -$17.94M | – |
| Q4 FY2020 | Dec 31, 2020 | -$17.66M | – |
| Q3 FY2020 | Sep 30, 2020 | -$16.98M | – |
| Q2 FY2020 | Jun 30, 2020 | -$14.66M | – |
| Q1 FY2020 | Mar 31, 2020 | -$10.58M | – |
| Q4 FY2019 | Dec 31, 2019 | -$10.88M | – |
| Q3 FY2019 | Sep 30, 2019 | -$16.98M | – |
| Q2 FY2019 | Jun 30, 2019 | -$13.41M | – |
| Q1 FY2019 | Mar 31, 2019 | -$10.44M | – |
| Q4 FY2018 | Dec 31, 2018 | -$8.05M | -453.2% |
| Q3 FY2018 | Sep 30, 2018 | -$8.55M | – |
| Q2 FY2018 | Jun 30, 2018 | -$6.38M | – |
| Q1 FY2018 | Mar 31, 2018 | -$6.11M | – |
| Q4 FY2017 | Dec 31, 2017 | $2.28M | – |
| Q3 FY2017 | Sep 30, 2017 | -$13.06M | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.64M | – |
| Q1 FY2017 | Mar 31, 2017 | -$5.83M | – |
See a number that looks wrong?